Clinical significance of the changes of platelet counts and serum thrombopoietin levels in chronic hepatitis C patients treated with different doses of consensus interferon

Hepatology Research

Volumn 24, Issue 3, 2002, Pages 236-244

  Chu, Chen Wei ^a   Hwang, Shinn Jang ^a   Lu, Rei Hwa ^a   Lai, Chiung Ru ^a   Luo, Jiing Chyuan ^a   Wang, Yuan Jen ^a   Chang, Full Young ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; Consensus interferon; Thrombocytopenia; Thrombopoietin

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CONSENSUS INTERFERON; PLACEBO; THROMBOPOIETIN; VIRUS RNA;

ADULT; AGE; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE MARKER; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HORMONE BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARAMETER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0036847382     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00108-0     Document Type: Article

References (39)

1. Tahara T, Usuki K, Sato H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996;93:783-8.
2. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996;88:2578-84.
3. Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997;25:1-7.
4. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1997;89:101-7.
5. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995;86:3668-75.
6. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-8.
7. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996;87:567-73.
8. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to increased platelet destruction. Blood 1996;87:1896-904.
9. Hino M, Nishizawa Y, Tagawa S, Yamane T, Morii H, Tatsumi N. Constitutive expression of the thrombopoietin gene in a human hepatoma cell line. Biochem Biophys Res Commun 1995;217:475-81.
10. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
11. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
12. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
13. Shimodaira S, Ishida F, Ichikawa N, et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemostasis 1996;76:545-8.
14. Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997;25:565-72.
15. Hoofnagle JH, de Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
16. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-62.
17. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
18. Pardo M, Marriott E, Moliner MC, Quiroga JA, Carreno V. Risks and benefits of interferon-alpha in the treatment of hepatitis. Drug Safety 1995;13:304-16.
19. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997;27:127-31.
20. Ishikawa T, Ichida T, Matsuda Y, et al. Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol 1998;13:907-13.
21. Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interf Cytok Res 1995;15:611-6.
22. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol 1999;14(Suppl.):12-8.
23. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992;12:55-9.
24. Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak mRNA accumulation at lower concentration than interferon-a 2a. J Interferon Res 1993;13:341-7.
25. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon alpha species, consensus interferon. J Interferon Cytok Res 1996;16:489-99.
26. Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic patients with chronic hepatitis C. Am J Gastroenterol 1999;94:2496-500.
27. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-6.
28. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
29. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
30. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primer for specific detection. J Gen Virol 1993;74:2385-90.
31. Simmonds P, McOmish F, Yap PL, et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993;74:661-8.
32. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
33. Luo JC, Hwang SJ, Lai CR, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. J Gastroenterol Hepatol 1998;13:685-90.
34. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-71.
35. Martin TG, 3rd, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285-8.
36. Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 1999;29:1739-42.
37. Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973-8.
38. Tomita N, Motomura S, Sakai R, et al. Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia. Am J Hematol 2000;63:131-5.
39. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132:364-8.